Delivery Order SPE2DB20D1047-SPE2DB25FF84W
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $11,161.15 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pen injections on August 5, 2025, with completion scheduled for August 6, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded competitively through an open procurement process. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- AmerisourceBergen Drug Corp was awarded a $12,668.89 delivery order by the Defense Logistics Agency (DLA) on September 17, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections (0.5 mL). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of September 18, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under...
- The Defense Logistics Agency awarded a $7,509.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections on August 19, 2025, with ultimate completion scheduled for August 20, 2025. This competitive award, placed under no set-aside designation, represents a child delivery order issued against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor agreement...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $1,143.87 firm fixed-price delivery order on July 22, 2025, for Zepbound 15 mg/0.5 ml pen injections. This is a competitively awarded, non-set-aside contract with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and an ultimate completion date of July 23, 2025. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $4,345.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp for supply of Zepbound 5 mg/0.5 mL pen injections, with an ultimate completion date of June 9, 2025. This competitively awarded contract, issued without set-aside designation, leverages AmerisourceBergen's established relationship with DLA as a critical pharmaceutical distributor supporting federal medical procurement. The contract represents a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injections, valued at $6,035.72. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is scheduled for completion by August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist...
- The Defense Logistics Agency awarded a delivery order valued at $6,750.31 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $3,188.64 to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections on July 22, 2025, with an ultimate completion date of July 23, 2025. This is a firm fixed price, non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a delivery order valued at $8,842.24 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injectors on September 10, 2025, with completion targeted for September 11, 2025. This non-competitive, firm fixed-price delivery order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. The award represents a child contract action under...
- The Defense Logistics Agency awarded a delivery order valued at $2,690.13 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on August 18, 2025, with completion targeted for August 19, 2025. This competitive, firm fixed-price delivery order was placed against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical prime vendor agreement running through December 2026. The...
- SPE2DB20D1047Indefinite Delivery Contract
- SPE2DB20D1047-SPE2DB25FF84WDelivery Order
The Defense Logistics Agency awarded a $12,688.64 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for Zepbound 12.5 mg/0.5 mL pen injections with a completion date of September 16, 2025. This competitively awarded, non-set-aside contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. The delivery is to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, supplying the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems with a comprehensive range of medications and medical supplies. Zepbound is a GLP-1 receptor agonist used for chronic weight management, reflecting the company's role in delivering specialized pharmaceutical products across multiple therapeutic domains to support military and federal healthcare programs. As a major pharmaceutical distributor with demonstrated capability to meet federal procurement requirements through open competition, AmerisourceBergen continues to serve as a prime vendor for the DLA's global pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.7k | 9/15/25 |